DOCSLIB.ORG

ECN72020 CRP4 V2000845.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ECN72020 CRP4 V2000845.Pdf E/CN.7/2020/CRP.4 31 January 2020 English only Commission on Narcotic Drugs Sixty-third session Vienna, 2–6 March 2020 Item 5 (a) of the provisional agenda* Implementation of the international drug control treaties: changes in the scope of control of substances Compilation of all questions and answers on the WHO recommendations on cannabis and cannabis-related substances raised during the fourth and fifth intersessional meeting of the Commission at its sixty-second session** 1. At its sixty-second regular session, on 19 March 2019, the Commission decided to postpone the voting on the recommendations of the World Health Organization (WHO) on the scope of control of cannabis and cannabis-related substances, in order to provide States with more time to consider the recommendations (Decision 62/14). 2. During the fourth and the fifth intersessional meeting of the Commission at its sixty-second session, which were held on 24 June 2019 and 23 September 2019, the Commission considered the WHO recommendations on cannabis and cannabis- related substances and had the opportunity to address questions to representatives of the WHO. The International Narcotics Control Board and UNODC were also present to provide answers within their respective mandates. 3. Questions and answers submitted in writing before and after the intersessional meetings were circulated among delegations via special messages and were made available online on the Commission’s website. This document contains a compilation of all questions and answers structured by recommendation. __________________ * E/CN.7/2020/1. ** This document has not been edited. V.20-00845 (E) *2000845* E/CN.7/2020/CRP.4 Questions and answers relating to WHO’s recommendations on cannabis and cannabis- related substances Status: 26 November 2019 Contents 5.0 General Questions ........................................................................................................................ 4 a) Written answers circulated on 2 July 2019 ........................................................................................ 4 b) Written answers circulated on 30 July 2019 ....................................................................................... 5 c) Written answers circulated on 4 October 2019 ................................................................................... 7 d) Written answers circulated on 21 October 2019 ...............................................................................10 e) Written answers circulated on 26 November 2019 ...........................................................................12 5.1 Cannabis and Cannabis Resin ....................................................................................................17 a) Written answers circulated on 2 July 2019 ......................................................................................17 b) Written answers circulated on 30 July 2019 .....................................................................................20 c) Written answers circulated on 4 October 2019 .................................................................................23 d) Written answers circulated on 21 October 2019 ...............................................................................26 e) Written answers circulated on 26 November 2019 ...........................................................................26 5.2 Delta-9-tetrahydrocannabinol (dronabinol)..................................................................................28 a) Written answers circulated on 2 July 2019 ......................................................................................28 b) Written answers circulated on 30 July 2019 .....................................................................................31 c) Written answers circulated on 4 October 2019 .................................................................................33 d) Written answers circulated on 21 October 2019 ...............................................................................38 e) Written answers circulated on 26 November 2019 ...........................................................................40 5.3 Tetrahydrocannabinol (isomers of THC) .....................................................................................43 a) Written answers circulated on 2 July 2019 ......................................................................................43 b) Written answers circulated on 4 October 2019 .................................................................................44 5.4 Extracts and tinctures of cannabis .............................................................................................45 a) Written answers circulated on 2 July 2019 ......................................................................................45 b) Written answers circulated on 4 October 2019 .................................................................................48 c) Written answers circulated on 21 October 2019 ...............................................................................50 d) Written answers circulated on 26 November 2019 ...........................................................................50 5.5 Cannabidiol Preparations ...........................................................................................................52 a) Written answers circulated on 2 July 2019 ......................................................................................52 b) Written answers circulated on 30 July 2019 .....................................................................................59 c) Written answers circulated on 4 October 2019 .................................................................................60 e) Written answers circulated on 26 November 2019 ...........................................................................69 2/90 V.20-00845 E/CN.7/2020/CRP.4 5.6 Pharmaceutical Preparations of Cannabis and delta-9-tetrahydrocannabinol (Dronabinol) .........74 a) Written answers circulated on 2 July 2019 ......................................................................................74 b) Written answers circulated on 30 July 2019 .....................................................................................77 c) Written answers circulated on 4 October 2019 .................................................................................78 d) Written answers circulated on 26 November 2019 ...........................................................................82 Annex 1 – TABLE OF CONTROL MEASURES – LICIT ACTIVITIES ...........................................................84 Annex 2 – TABLE OF CONTROL MEASURES – PENAL PROVISIONS ......................................................87 V.20-00845 3/90 E/CN.7/2020/CRP.4 5.0 General Questions a) Written answers circulated on 2 July 2019 China 1) The research on the use of cannabis and cannabis plant in the fields of medicine and food, and the research outcomes, according to WHO. Elaboration on the evidence that benefits of research and utilization of preparations of cannabis are greater than risks. 2) How to research and develop CBD while reasonably control the amount of delta-9-THC in the preparations, given that CBD and delta-9-THC exist concurrently in cannabis plant European 1) How do these recommendations link with the warning issued by the International Union Narcotics Control Board, at the occasion of the launch of its Annual Report 2018, of the dangers of non-medical cannabis developments? 2) How will the implementation of these recommendations affect cannabis-related products, for example CBD-products, on the market? 3) Would you think it might be helpful to have a Glossary which lists and explains more clearly and separate the cannabis related terms due to the medical use or non- medical use (illicit use)? 4) A lack of clarity was identified in relation to the following aspects related to the WHO recommendations on cannabis and cannabis-related substances: - the impact on food products: the current legislation, both at international and at national, does not allow the presence of THC in food products, including the sorts that are considered technical and for food production for example seeds, seed oil, leaves, etc. The legislation requires zero presence of THC, however in practice this is not feasible and small amount of THC is present in these products. For this reason, in some European Union countries national THC limits in food exist, whereas in some others do not consider the national limit as it would violate international conventions. - the impact on the use of CBD in food, having in mind that there is a high interest of producers in adding CBD to foods. It is to be noted that deliberate addition of CBD to food is considered a novel food. 5) Member States should be able to form their own opinion on the relevant information regarding the process and the content of the WHO recommendations. This information should be easily accessible and understandable also by those who are not scientists or legal experts. For example, this information concerns: voting procedures: for example, it should be clear that it does not just concern one vote but 6 votes on the 6 recommendations; scheduling and the related control measures; relevant background information on the recommendations: - It is not very clear where to find the right information on the WHO - ECDD website. The full report and peer reviews, or references to where to find them on the website could also
Load more

Recommended publications
  • The Role of Organic Small Molecules in Pain Management
    molecules Review The Role of Organic Small Molecules in Pain Management Sebastián A. Cuesta and Lorena Meneses * Laboratorio de Química Computacional, Facultad de Ciencias Exactas y Naturales, Escuela de Ciencias Químicas, Pontificia Universidad Católica del Ecuador, Av. 12 de Octubre 1076 Apartado, Quito 17-01-2184, Ecuador; [email protected] * Correspondence: [email protected]; Tel.: +593-2-2991700 (ext. 1854) Abstract: In this review, a timeline starting at the willow bark and ending in the latest discoveries of analgesic and anti-inflammatory drugs will be discussed. Furthermore, the chemical features of the different small organic molecules that have been used in pain management will be studied. Then, the mechanism of different types of pain will be assessed, including neuropathic pain, inflammatory pain, and the relationship found between oxidative stress and pain. This will include obtaining insights into the cyclooxygenase action mechanism of nonsteroidal anti-inflammatory drugs (NSAID) such as ibuprofen and etoricoxib and the structural difference between the two cyclooxygenase isoforms leading to a selective inhibition, the action mechanism of pregabalin and its use in chronic neuropathic pain, new theories and studies on the analgesic action mechanism of paracetamol and how changes in its structure can lead to better characteristics of this drug, and cannabinoid action mechanism in managing pain through a cannabinoid receptor mechanism. Finally, an overview of the different approaches science is taking to develop more efficient molecules for pain treatment will be presented. Keywords: anti-inflammatory drugs; QSAR; pain management; cyclooxygenase; multitarget drug; Citation: Cuesta, S.A.; Meneses, L. cannabinoid; neuropathic pain The Role of Organic Small Molecules in Pain Management.
    [Show full text]
  • Cannabis (Sub)Culture, the Subcultural Repository, and Networked Mediation
    SIMULATED SESSIONS: CANNABIS (SUB)CULTURE, THE SUBCULTURAL REPOSITORY, AND NETWORKED MEDIATION Nathan J. Micinski A Thesis Submitted to the Graduate College of Bowling Green State University in partial fulfillment of the requirements for the degree of MASTER OF ARTS May 2014 Committee: Ellen Berry, Advisor Rob Sloane © 2014 Nathan Micinski All Rights Reserved iii ABSTRACT Ellen Berry, Advisor Subcultural theory is traditionally rooted in notions of social deviance or resistance. The criteria for determining who or what qualifies as subcultures, and the most effective ways to study them, are based on these assumptions. This project seeks to address these traditional modes of studying subcultures and discover ways in which their modification may lead to new understandings and ways of studying subcultures in the contemporary moment. This will be done by suggesting a change in the criteria of examining subcultures from that of deviance or resistance to identification with a collection of images, symbols, rituals, and narratives. The importance of this distinction is the ability to utilize the insights that studying subcultures can offer while avoiding the faults inherent in speaking for or at a subculture rather than with or from it. Beyond addressing theoretical concerns, this thesis aims to apply notions of subcultural theory to study the online community of Reddit, in particular, a subset known as r/trees–a virtual repository for those images, symbols, rituals, and narratives of cannabis subculture. R/trees illustrates the life and vibrancy of a unique subcultural entity, which to this point has evaded a cultural studies analysis. To that end, this project advocates for the importance of the cultural studies approach to analyzing cannabis subculture and further, to insert the findings of this study into that gap in the literature.
    [Show full text]
  • Extracts and Tinctures of Cannabis
    WHO Expert Committee on Drug Dependence Critical Review …………….. Extracts and tinctures of cannabis This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization © World Health Organization 2018 All rights reserved. This is an advance copy distributed to the participants of the 41st Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
    [Show full text]
  • Guide to Worker Safety and Health in the Marijuana Industry Marijuana Occupational Health and Safety Work Group January 2017
    Guide to Worker Safety and Health in the Marijuana Industry Marijuana Occupational Health and Safety Work Group January 2017 colorado.gov/cdphe/marijuana-occupational-safety-health Guide to Worker Safety and Health in the Marijuana Industry: 2017 About this guide This guide is intended to help assist employers in the marijuana industry build occupational safety and health programs. While the foundation of this guide includes existing Colorado state and federal regulations, it is not a comprehensive guide to all of the regulations pertaining to occupational safety and health. It should be noted that this guide does not present any new occupational safety and health regulations for the marijuana industry. Marijuana cultivators, extractors, labs and retailers are required to adhere to all regulations established by the Colorado Department of Revenue’s Marijuana Enforcement Division (MED) https://www.colorado.gov/pacific/enforcement/laws-constitution-statutes-and-regulations-marijuana- enforcement. The marijuana industry in Colorado falls under federal OSHA jurisdiction and businesses must comply with OSHA regulations and recordkeeping requirements. In addition to OSHA regulations, marijuana businesses are required to comply with other state regulations including Colorado labor laws, Colorado workers’ compensation laws, Colorado hazardous waste laws, Colorado Pesticide Applicator’s Act, local fire codes, and other regulations that are specific to employment and labor as well as the production of retail and medical marijuana. Guide to Worker Safety and Health in the Marijuana Industry: 2017 About the Colorado Marijuana Occupational Health and Safety Work Group The Colorado Marijuana Occupational Health and Safety Work Group is a multidisciplinary group that was convened to draw on expertise and experiences of many professionals in the Colorado community.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Cannabis Alchemy
    Contents Preface Introduction Chapter One Extraction & Purification of Marijuana & Hashish Oils Chapter Two Isomerization Chapter Three THC Acetate Chapter Four Preparation of Hashish Chapter Five Increasing Potency of Intact Marijuana Flowers Chapter Six Preparation of Oil Capsules Chapter Seven Smoking Oil by Direct Vaporization Chapter Eight Preparation of Translucent (Honey) Oil Chapter Nine Preparation of “Reefers” Chapter Ten High-Volume Extraction Method Chapter Eleven Advanced Refinement Techniques Appendix A Letters Appendix B Solvent Notes Glossary References D. Gold reveals the inner world of marijuana and hashish in CANNABIS ALCHEMY. Accompany the alchemist as he uncovers the secrets of enhancing potency in this informative text. “Cannabis lovers awake and sing! For this is surely no less than a masterwork, a lucid, extraordinarily practical labor of alchemical love and lore.” David Solomon, author of “Marijuana Papers” “This modern classic adds a valid new twist to the ancient art of getting high.” George Andrews, author of “The Book of Grass” Preface The cultivation of marijuana and the refinement of its preparations has concerned alchemists and hedonists on this planet for centuries. Cannabis sativa and Cannabis indica are both powerful allies. The body of the plant itself serves as a link between the physical plane and a host of Spirits of exceptional wisdom and subtlety. When the plant is ingested, these qualities are manifested in the. mind of the worshipper, unlocking the storehouse of Wisdom within and revealing the hidden springs of pleasure. Smoking or eating the leaves or flowers is usually sufficient to bring about the desired state, although it seems inherent in the nature of Man to search for more concentrated forms of the drug that are stronger, more pleasant to ingest, or more desirable in some other way.
    [Show full text]
  • Urine Drug Screening (UDS)
    Centre for Effective Practice Urine Drug Screening (UDS) Table 1: Why, who, and when? Why do UDS?1,2,3 Which patients should receive UDS? When should UDS be ordered?1 • Improve safety, encourage • Should be used routinely • At baseline (when receiving a new communication, and promote regardless of how well the patient or opioids or starting an opioid transparency of drug use patient is known to the trial) • Establish reliability of patient’s prescriber • At follow-up after initiation reported medication history • A universal approach will • Then annually or more frequently if high • Monitor adherence and detect help destigmatize testing risk or aberrant drug-related behaviours potential diversion • “I do this routinely for all of • Consider testing randomly to minimize my patients on opioids” potential for tampering Table 2: Immunoassay vs. broad spectrum (mass spec/chromatography)2,3 Immunoassay (IA) Gas Chromatography/Mass Spectrometry (GCMS) Liquid Chromatography/Tandem Mass Spectrometry (LC- MS/MS) Use Screening test Reserved for confirmatory testing (due to expense and Presumptive only; confirmatory testing needed for time required) significant decisions (e.g. legal/employment/forensic) Interpretation Does not differentiate between various opioids Differentiates: codeine, morphine, oxycodone, May not detect: hydromorphone, heroin • Semi-synthetic opioids (e.g. buprenorphine, More sensitive for semi-synthetic and synthetic opioids hydrocodone, hydromorphone, oxycodone, Sensitivity will depend on individual laboratory cut-off levorphanol)
    [Show full text]
  • (A-9-THC) Content in Herbal Cannabis Over Time
    32 Current Drug Abuse Reviews, 2012, 5, 32-40 Increasing Delta-9-Tetrahydrocannabinol (-9-THC) Content in Herbal Cannabis Over Time: Systematic Review and Meta-Analysis Fidelia Cascini*,1, Carola Aiello2 and GianLuca Di Tanna3 1Istituto di Medicina Legale, Università Cattolica del S. Cuore, largo F. Vito, 1 00168 Roma, Italy 2Department of Informatics and Systemics, University ‘La Sapienza’, 00185 Rome, Italy 3Department of Public Health and Infectious Diseases, University "La Sapienza", 00185, Rome, Italy Abstract: Aim: The objective of this meta-analysis is to assess the data regarding changes in herbal cannabis potency over time (from 1970 to 2009). Methods: Systematic searches of 17 electronic scientific databases identified studies on this topic, within which 21 case series studies satisfied our inclusion criteria of reporting the mean tetrahydrocannabinol (THC) value per number of samples per year. No language, publication date, publication type or status restrictions were imposed. The study selection and data extraction processes were performed independently but uniformly by two authors, included screening, determination of eligibility and inclusion of the eligible studies in the systematic review, and a meta-analysis of the results on THC content in herbal cannabis samples. We considered papers and not monographic scientific publications, rejecting all studies that were not focused on the subject of this review. Results: Meta-analysis by year was performed on 21 studies containing 75 total mean THC observations from 1979 to 2009 using the random effects model. The results revealed much variability between studies. Further, there was a significant correlation between year and mean THC in herbal cannabis. The combined data indicated the correlation between year and mean THC in herbal cannabis, revealing a temporal trend of increasing potency (5% above the mean THC value in the Poisson regression analysis).
    [Show full text]
  • The Pet Issue P12
    M A G A Z I N E BOUTIQUE CANNABIS CULTURE 08 22 HOW CANNABIS CAN HELP YOUR PET Through the consumption of cannabinoids, your pet can receive the same incredible benefits as humans. The Pet Issue p12 Letter From the Editor The Meeting Place for Industry Innovators PUBLISHER CHRISTINA DEGIOVANNI March 20-22, 2017 MANAGING EDITOR JAANA PRALL Oakland Marriott City Center Cannabis 2017 is different than any other event in the market. In addition to its Oakland, CA EDITOR-AT-LARGE MELISSA HUTSELL unique combination of educational programming on both cultivation and busi- ASSISTANT COPY EDITOR MELODY HAYHURST As the legal ness management, it has been developed by cultivators, for cultivators. cannabis GRAPHICS TANYA NORDBERG | NATHAN WELLS industry Join industry leaders, CEOs, executive team members and innovators for 2½ evolves, the need SOCIAL MEDIA MANAGER JESSICA BARFIELD intense days of interactive learning and networking as we move the industry for legitimate COVER SHOT @TREETOPGARDENS_ “cultivation and forward at Cannabis 2017. business management information is at an FEATURED SPEAKERS INCLUDE: CONTRIBUTORS all-time high. Cannabis MOLLY CATE | LESLIE CLARY | ART COSGROVE 2017 provides an BROKKE GEHRING DAVID BONVILLAIN TODD HILL ALLISON EDRINGTON | EMILY HOBELMANN unparalleled education MELISSA HUTSELL | JEFF THE 420 CHEF program that will be SHARON LETTS | PAM LONG | NORA MOUNCE crucial to those who SHANNON PERKINS | ASHLEY PRIEST want to thrive in this JAMES PRIEST | DIANA TRIMBLE industry.” Ken Morrow, Owner, Trichome Technologies PHOTOGRAPHY CANNABIS 2017 CONFERENCE CHAIR PATRICK ANDERSON | 8 MILE FAMILY FARM CEO Founder and CEO Founder/Managing Principal @BAKEDINHUMBOLDT | @COASTALFOGFARMS Dear Reader, FGS Inc.
    [Show full text]
  • Marijuana: What the Evidence Shows at It Relates to the Impact of Use and What Can Be Learned from Washington State and Colorado.”
    Kevin A. Sabet, Ph.D. Director, University of Florida Drug Policy Institute, Department of Psychiatry, Division of Addiction Medicine Director, Project SAM (Smart Approaches to Marijuana) Author, Reefer Sanity: Seven Great Myths About Marijuana Before the House and Senate Judiciary Committees, State of Oregon January 17, 2013 Written Testimony “Marijuana: What the evidence shows at it relates to the impact of use and what can be learned from Washington State and Colorado.” Chairman and distinguished members of the Committee, thank you for providing me with the opportunity to appear before you today to discuss marijuana policy and appropriate federal responses. I have studied, researched, and written about drug policy, drug markets, drug prevention, drug treatment, criminal justice policy, addiction, and public policy analysis for almost 18 years. Most recently, from 2009-2011, I served in the Obama Administration as a senior drug policy advisor. I am currently the co-founder, with former Congressman Patrick J. Kennedy, of Project SAM (Smart Approaches to Marijuana). I am also the author of Reefer Sanity: Seven Great Myths About Marijuana (Beaufort). In fact, in my new book, I outline the precise reasons why we in the Obama Administration rejected legalization time and time again when presented with it. Our experience, when talking with parents, prevention and treatment providers, medical associations, law enforcement, and others, was that opening up a legal market for any current illicit drug would be disastrous for public health and safety. Indeed, in the Obama Administration’s inaugural and subsequent drug control strategies, marijuana legalization is explicitly rejected. That is why numerous groups and I found the recent guidance by the U.S.
    [Show full text]
  • The Handbook of Cannabis Therapeutics: from Bench to Bedside
    Handbook of Cannabis Therapeutics From Bench to Bedside 9780789030979 Handbook of Cannabis Therapeutics From Bench to Bedside Size: 212 x 152mm Spine size: 26 mm Color pages: Binding: Paperback THE HAWORTH PRESS® Haworth Series in Integrative Healing Ethan Russo Editor The Last Sorcerer: Echoes of the Rainforest by Ethan Russo Professionalism and Ethics in Complementary and Alternative Medicine by John Crellin and Fernando Ania Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential by Franjo Grotenhermen and Ethan Russo Modern Psychology and Ancient Wisdom: Psychological Healing Practices from the World’s Religious Traditions edited by Sharon G. Mijares Complementary and Alternative Medicine: Clinic Design by Robert A. Roush Herbal Voices: American Herbalism Through the Words of American Herbalists by Anne K. Dougherty The Healing Power of Chinese Herbs and Medicinal Recipes by Joseph P. Hou and Youyu Jin Alternative Therapies in the Treatment of Brain Injury and Neurobehavioral Disorders: A Practical Guide edited by Gregory J. Murrey Handbook of Cannabis Therapeutics: From Bench to Bedside edited by Ethan B. Russo and Franjo Grotenhermen Handbook of Cannabis Therapeutics From Bench to Bedside Ethan B. Russo, MD Franjo Grotenhermen, MD Editors Routledge Taylor &. Francis Croup NEW YORK AND LONDON First Published by The Haworth Press, Inc., 10 Alice Street, Binghamton, NY 13904-1580. Transferred to Digital Printing 2010 by Routledge 270 Madison Ave, New York NY 10016 2 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN For more information on this book or to order, visit http://www.haworthpress.com/store/product.asp?sku=5741 or call 1-800-HAWORTH (800-429-6784) in the United States and Canada or (607) 722-5857 outside the United States and Canada or contact [email protected] © 2006 by The Haworth Press, Inc.
    [Show full text]
  • Cannabis and Cannabinoids for Medical, Scientific and “Recreational” Use: Risks and Benefits
    Chapter I. Cannabis and cannabinoids for medical, scientific and “recreational” use: risks and benefits 1. The Governments of several States have passed drug control treaties, resulting in the diversion of legislation allowing patients suffering from certain health cannabis to non-medical use. In several countries, poorly conditions (such as terminal cancer, epilepsy and neuro- regulated medical cannabis programmes and the associated logical illnesses) to use cannabinoids and cannabis to treat lower perception of risk may have contributed to the the symptoms of their illnesses (see box 1 for definitions legalization of non-medical cannabis use, contrary to the of key terms). Some medical cannabis programmes have international drug control treaties (see para. 5 and sections had an adverse impact on public health because they have H–K below). not been effectively regulated in line with the international Box 1. Some key terms 1. “Cannabis and its derivatives” describes all products derived from the cannabis plant. Cannabis plant prod- ucts include the flowering tops (marijuana), compressed cannabis resin (hashish), cannabis oils, concentrated cannabis extracts (waxes) and edible preparations (e.g., infusions, cookies and chocolates). 2. Cannabinoids are substances found only in the cannabis plant. There are estimated to be 104 unique, nat- urally occurring cannabinoids but the 2 that have been most extensively studied are THC and CBD: • THC produces the psychoactive effects, such as euphoria, relaxation and heightened sensory experi- ences, sought by “recreational” users • CBD has few psychoactive effects. It may moderate the psychoactive effects of THC and has antioxidant, anti-inflammatory and neuroprotective effects 3. Synthetic cannabinoids are substances produced in the laboratory that have similar effects to THC or other cannabinoids (e.g., nabilone).
    [Show full text]